Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

Brentuximab vedotin (Adcetris, Takeda) is indicated for 'adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and ...

Brentuximab vedotin (Adcetris) with doxorubicin, dacarbazine and vinblastine is available on the NHS. It is a possible treatment for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.

The global antibody drug conjugate (ADC) market is thriving, fueled by rising cancer prevalence, technological advancements, and demand for targeted therapies. ADCs, which merge monoclonal antibodies ...

The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies ...

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shar ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Post this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev and Tivdak — all approved across solid tumors and hematologic malignancies. These products contributed ...

It could rival or exceed the value of Keytruda, Enhertu, or Adcetris. • A full validation in both hematology and solid tumors would command a $15B–$30B+ valuation. • Even today, with MDS ...